4.7 Article

Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease

Journal

NEUROBIOLOGY OF DISEASE
Volume 155, Issue -, Pages -

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2021.105368

Keywords

Axon destruction; Sarm1; Alpha-synuclein; Axotomy; Parkinson's disease

Categories

Funding

  1. Michael J Fox Foundation Target Validation grant
  2. NIH [R01 NS059991, R01 NS110879, R01 NS111990]
  3. Angel Fund for ALS Research
  4. ALSOne
  5. ALS Finding a Cure
  6. Cellucci Fund for ALS Research
  7. Max Rosenfeld Fund

Ask authors/readers for more resources

Parkinson's disease is a neurodegenerative movement disorder linked to profound loss of dopaminergic neurons in the basal ganglia. Studies suggest that Sarm1 contributes to degeneration of dopaminergic projections in the nigrostriatal tract, but its role may vary in different models of PD.
Parkinson's disease (PD) is the most common form of neurodegenerative movement disorder, associated with profound loss of dopaminergic neurons from the basal ganglia. Though loss of dopaminergic neuron cell bodies from the substantia nigra pars compacta is a well-studied feature, atrophy and loss of their axons within the nigrostriatal tract is also emerging as an early event in disease progression. Genes that drive the Wallerian degeneration, like Sterile alpha and toll/interleukin-1 receptor motif containing (Sarm1), are excellent candidates for driving this axon degeneration, given similarities in the morphology of axon degeneration after axotomy and in PD. In the present study we assessed whether Sarm1 contributes to loss of dopaminergic projections in mouse models of PD. In Sarm1 deficient mice, we observed a significant delay in the degeneration of severed dopaminergic axons distal to a 6-OHDA lesion of the medial forebrain bundle (MFB) in the nigrostriatal tract, and an accompanying rescue of morphological, biochemical and behavioural phenotypes. However, we observed no difference compared to controls when striatal terminals were lesioned with 6-OHDA to induce a dying back form of neurodegeneration. Likewise, when PD phenotypes were induced using AAV-induced alpha-synuclein overexpression, we observed similar modest loss of dopaminergic terminals in Sarm1 knockouts and controls. Our data argues that axon degeneration after MFB lesion is Sarm1-dependent, but that other models for PD do not require Sarm1, or that Sarm1 acts with other redundant genetic pathways. This work adds to a growing body of evidence indicating Sarm1 contributes to some, but not all types of neurodegeneration, and supports the notion that while axon degeneration in many context appears morphologically similar, a diversity of axon degeneration programs exist.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available